Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11302
Title: In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
Authors: Villemagne, Victor L;Okamura, Nobuyuki;Pejoska, Svetlana;Drago, John;Mulligan, Rachel S;Chételat, Gaël;Ackermann, Uwe;O'Keefe, Graeme J;Jones, Gareth;Gong, Sylvia J;Tochon-Danguy, Henry;Kung, Hank F;Masters, Colin L;Skovronsky, Daniel M;Rowe, Christopher C
Affiliation: Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health, Heidelber, Australia. villemagne@petnm.unimelb.edu.au
Issue Date: 1-Jul-2011
Citation: Archives of Neurology; 68(7): 905-12
Abstract: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand (18)F 9-fluropropyl-(+)-dihydrotetrabenazine ([(18)F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD).Nine patients with DLB, 10 patients with AD, 20 patients with Parkinson disease (PD), and 10 healthy age-matched control subjects underwent [(18)F]AV-133 positron emission tomography studies. VMAT2 density was calculated through normalized tissue uptake value ratios at 120 to 140 minutes postinjection using the primary visual cortex as the reference region.Comparison of the tissue ratio for [(18)F]AV-133 between the different clinical diagnostic groups.Lower VMAT2 densities were observed in patients with DLB when compared with patients with AD especially in the posterior putamen (caudate: mean [SD], 1.24 [0.6] vs 2.83 [0.9]; P < .001; effect size = 2.1; anterior putamen: mean [SD], 0.90 [0.5] vs 3.01 [0.9]; P < .001; effect size = 2.9; posterior putamen: mean [SD], 0.62 [0.5] vs 2.87 [0.8]; P < .001; effect size = 3.4). Compared with healthy controls, [(18)F]AV-133 tissue ratios were significantly lower by 88% and 74% in the posterior putamen, 74% and 65% in the anterior putamen, and 53% and 51% in the caudate nucleus of patients with PD and DLB, respectively. In contrast to patients with PD and DLB, no reductions were observed in patients with AD.[(18)F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. [(18)F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in patients with DLB and assist in the differential diagnosis from AD.
Internal ID Number: 21747030
URI: http://ahro.austin.org.au/austinjspui/handle/1/11302
DOI: 10.1001/archneurol.2011.142
URL: http://www.ncbi.nlm.nih.gov/pubmed/21747030
Type: Journal Article
Subjects: Aged
Aged, 80 and over
Alzheimer Disease.radionuclide imaging
Area Under Curve
Brain Mapping
Female
Fluorine Radioisotopes
Humans
Lewy Body Disease.radionuclide imaging
Male
Middle Aged
Positron-Emission Tomography.methods
ROC Curve
Tetrabenazine.analogs & derivatives.diagnostic use
Vesicular Monoamine Transport Proteins.metabolism
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.